Search Results

KBI Biopharma, Inc. today announced the appointment of Jean-Baptiste (JB) Agnus as Chief Business Officer, solidifying KBI’s Executive Team.

KBI Biopharma, Inc., a JSR Life Sciences company and cGMP contract development and manufacturing organization, announced the appointment of Peter Carbone as the new Chief Quality Officer, strengthening KBI’s expertise in Quality and Regulatory Affairs.

KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced the launch of SUREmAb ™, an offering built on the robustness of KBI’s SUREtechnology Platform™, that allows for optimized, safe, and cost-efficient monoclonal antibody (mAb) development and manufacturing.

KBI Biopharma, Inc., a JSR Life Sciences company, announced the recent appointment of Maggie Chen, Senior Vice President and Site Head of the Patriot Park mammalian cGMP manufacturing facility in Durham, North Carolina.

KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced four recent executive appointments to continue its momentum and vision of becoming a next-generation CDMO.

KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced the launch of KBI PUREplatform™, a premium microbial cell line development (CLD) platform that features unmatched efficiencies in a microbial expression system for biopharmaceutical production.

KBI Biopharma, Inc., a JSR Life Sciences company and cGMP contract development and manufacturing organization, and Argonaut Manufacturing Services, Inc., a cGMP contract manufacturing organization serving the biopharmaceutical and diagnostics industries, announced a strategic alliance offering biopharmaceutical clients with end-to-end drug substance and drug product manufacturing solutions.

2023 marked the most bankruptcies in biopharma in more than a decade, with 14 companies filing for Chapter 11 protection. The number remained high in 2024.

From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma’s most competitive therapeutic spaces—and attracting dollars from Big Pharma.